ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025

Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing experience

Read more at globenewswire.com